So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...

Gilead Sciences (NasdaqGS:GILD) recently experienced a significant price movement, rising 24% in the last quarter. This ...

Biktarvy Demonstrates High Rates of Viral Suppression in People with HIV/HBV Coinfection ALLIANCE (NCT03547908) is an ongoing Phase 3 study evaluating Biktarvy versus dolutegravir 50 mg (DTG ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

(RTTNews) - Gilead Sciences, Inc. (GILD) Wednesday said it presented encouraging long-term data from ALLIANCE study. ALLIANCE is an ongoing Phase 3 study to evaluate Biktarvy versus dolutegravir ...

MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

To manage risk, investors should diversify their stock portfolio across industries and this could be the stock to study in the pharmaceutical sector for the long haul.

“Gilead is fueling the next wave of innovation ... vital importance of catalyzing research reaching towards a cure.” Biktarvy Demonstrates High Rates of Viral Suppression in People with ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...